Book Cover
Home  |   Healthcare   |  Veterinary Infectious Disease Diagnostics Market

Veterinary Infectious Disease Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Immunodiagnostic, Molecular Diagnostic, Others), By Application (Reference Laboratories, Veterinary Laboratories and Clinics, Point of Care/In House Testing, Research Institutes and Universities), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Veterinary Infectious Disease Diagnostics Market Overview

The global Veterinary Infectious Disease Diagnostics Market is projected to experience sustained growth from USD 2439.08 Million in 2026 to USD 4879.77 Million by 2035, exhibiting a CAGR of 8.01% during the forecast period 2026-2035.

The Veterinary Infectious Disease Diagnostics Market is experiencing steady growth, driven by increasing companion-animal healthcare expenditure, expanding livestock disease surveillance, rising awareness of zoonotic infections, and growing demand for rapid pathogen detection technologies. Immunodiagnostic leads the product segment with approximately 46% market share, supported by its widespread use in routine infectious disease screening, antigen and antibody detection, veterinary clinical testing, and livestock health monitoring. Veterinary hospitals, diagnostic laboratories, and animal-health organizations are increasingly adopting advanced testing solutions to improve diagnostic accuracy, support early disease identification, strengthen biosecurity measures, and enable timely treatment decisions. Manufacturers are focusing on multiplex immunoassays, automated diagnostic platforms, portable testing devices, and digital result interpretation to enhance testing efficiency across companion and production animal populations.

The Veterinary Infectious Disease Diagnostics Market continues to benefit from expanding veterinary laboratory infrastructure, increasing adoption of molecular diagnostic technologies, growing demand for point-of-care testing, and greater investment in animal disease prevention programs. North America leads the global market with approximately 38% share, supported by established veterinary healthcare networks, extensive reference laboratory infrastructure, high companion-animal healthcare spending, and advanced livestock disease monitoring systems. The United States remains a major contributor due to strong veterinary diagnostic capabilities, commercial livestock production, and widespread adoption of rapid infectious disease testing. Continued innovation in PCR-based pathogen detection, automated sample preparation, multiplex diagnostic panels, and connected laboratory information systems is expected to strengthen market development and improve diagnostic accessibility across veterinary healthcare settings.

Global Veterinary Infectious Disease Diagnostics Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Rising companion-animal testing, livestock biosecurity, and infectious disease surveillance influence approximately 41% of Veterinary Infectious Disease Diagnostics Market expansion.
  • Major Market Restraint: Diagnostic cost, laboratory infrastructure gaps, and variable access to trained veterinary personnel create approximately 22% of adoption pressure.
  • Emerging Trends: Multiplex PCR, rapid point-of-care testing, digital interpretation, and automated molecular workflows represent approximately 34% of current diagnostic innovation activity.
  • Regional Leadership: North America leads the Veterinary Infectious Disease Diagnostics Market with approximately 38% share, supported by advanced veterinary infrastructure and laboratory networks.
  • Competitive Landscape: Multiplex assay launches, automated testing platforms, laboratory partnerships, and portfolio expansion represent approximately 28% of major competitive development activity.
  • Market Segmentation: Immunodiagnostic leads product demand with approximately 46% share, while Reference Laboratories dominate applications with approximately 36% share.
  • Recent Development: Rapid molecular testing and broader pathogen panels represent approximately 25% of recent veterinary infectious disease diagnostic development activity.

The Veterinary Infectious Disease Diagnostics Market is increasingly influenced by rapid molecular testing, multiplex pathogen detection, portable analyzers, and digital laboratory automation. Approximately 34% of current technology innovation focuses on PCR-based testing, multiplex panels, automated nucleic-acid preparation, and faster result interpretation. Molecular Diagnostic platforms are becoming increasingly important for infections where early identification, pathogen differentiation, and high analytical sensitivity are required. Veterinary laboratories are expanding respiratory, gastrointestinal, vector-borne, and reproductive disease panels so several pathogens can be evaluated from a single sample. Reference Laboratories are also investing in automated workflows to process larger testing volumes while maintaining consistency. 

Point of Care/In House Testing represents another important trend as veterinary practices seek faster clinical decisions and reduced dependence on external turnaround times. Approximately 31% of diagnostic modernization activity focuses on clinic-based analyzers, cartridge testing, portable immunoassays, and compact molecular systems. Rapid diagnostics are particularly valuable when veterinarians need immediate information about contagious disease, treatment isolation, or antimicrobial selection. Companion-animal clinics are expanding in-house testing for common infectious conditions, while livestock veterinarians increasingly use portable tools during herd and flock investigations.

Veterinary Infectious Disease Diagnostics Market Dynamics

Driver

"Growing animal health surveillance and faster infection detection are accelerating diagnostic adoption."

The strongest driver for the Veterinary Infectious Disease Diagnostics Market is the increasing need for earlier and more reliable detection of infectious disease across companion animals and commercial livestock. Approximately 41% of demand momentum is associated with routine screening, outbreak investigation, herd-health management, biosecurity, and clinical diagnosis. Faster detection allows veterinarians to separate infected animals, select more appropriate therapies, and reduce transmission within kennels, farms, shelters, and multi-animal households.

Livestock production and zoonotic disease surveillance provide an additional driver, with approximately 35% of growth-oriented diagnostic demand associated with poultry, cattle, swine, and other production-animal health programs. Infectious outbreaks can affect animal welfare, productivity, trade, and food supply, encouraging producers and veterinary authorities to strengthen monitoring. Molecular Diagnostic technologies are particularly useful where rapid pathogen identification and strain differentiation are required. Immunodiagnostic methods continue to support high-volume screening because they offer established workflows and broad disease coverage across veterinary environments.

Restraint

"Diagnostic cost and infrastructure limitations continue to restrict wider veterinary testing access."

The principal restraint affecting the Veterinary Infectious Disease Diagnostics Market is the uneven availability of advanced testing infrastructure across veterinary care settings. Approximately 22% of adoption pressure is associated with laboratory equipment requirements, assay cost, specialized personnel, sample handling, and limited access in rural animal-health environments. Molecular Diagnostic systems can provide high sensitivity and rapid pathogen identification, but laboratories require appropriate extraction, amplification, quality-control, and contamination-prevention procedures.

Variation in testing volumes and disease prevalence creates another restraint, with approximately 18% of implementation difficulty associated with maintaining cost-effective diagnostic menus across different animal populations. Companion-animal clinics may require frequent testing for common pathogens, whereas livestock operations can experience sudden demand spikes during outbreaks. Laboratories must balance assay availability, reagent storage, instrument utilization, and staffing without creating excessive unused capacity. Manufacturers are responding with modular platforms, smaller testing systems, and multiplex assays, but affordability remains an important consideration across emerging veterinary markets.

Opportunity

"Decentralized molecular testing and livestock surveillance create major expansion opportunities."

Point of Care/In House Testing represents one of the strongest opportunities in the Veterinary Infectious Disease Diagnostics Market. Approximately 34% of emerging commercial opportunity is associated with rapid clinic-based testing, portable molecular systems, cartridge diagnostics, and same-visit result delivery. Veterinary practices increasingly prefer tests that can support immediate clinical decisions without waiting for external laboratory results. Compact analyzers capable of detecting several pathogens from small sample volumes are particularly attractive for companion-animal hospitals, emergency clinics, and mobile veterinary services.

Livestock biosecurity and integrated surveillance provide another opportunity, with approximately 30% of future market development associated with herd screening, outbreak monitoring, and farm-level infectious disease control. Commercial producers increasingly require diagnostics that can identify pathogens before widespread transmission affects productivity. Portable molecular systems and high-throughput laboratory testing can complement each other by providing immediate field information followed by confirmatory analysis. 

Challenge

"Pathogen diversity and sample variability make diagnostic standardization technically demanding."

A major challenge in the Veterinary Infectious Disease Diagnostics Market is maintaining consistent diagnostic performance across multiple animal species, pathogen types, and sample conditions. Approximately 27% of technical complexity is associated with assay validation, sample quality, pathogen concentration, cross-reactivity, and species-specific biological differences. Veterinary diagnostics must often work with blood, serum, feces, swabs, tissue, milk, and other sample types, each presenting different analytical challenges. Manufacturers therefore need carefully validated protocols and quality-control procedures to maintain reliable sensitivity and specificity across testing environments.

Another challenge is keeping diagnostic panels current as pathogens evolve and disease patterns change. Approximately 23% of product-development effort focuses on new targets, assay updates, multiplex expansion, and emerging disease surveillance. Vector-borne diseases can shift geographically, while livestock pathogens can spread through animal movement and trade. Veterinary laboratories require platforms that can adapt quickly to changing testing priorities without replacing complete instrument systems. Flexible molecular panels, software-updatable interpretation, and modular reagent formats are becoming increasingly important for maintaining long-term diagnostic relevance.

Veterinary Infectious Disease Diagnostics Market Segmentation

Global Veterinary Infectious Disease Diagnostics Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Immunodiagnostic: Immunodiagnostic products are expected to dominate the Veterinary Infectious Disease Diagnostics Market with approximately 46% share. These tests remain widely used because they provide practical, established methods for detecting pathogen-specific antigens or antibodies across companion and production animals. Veterinary practices and laboratories use immunoassays for routine screening, outbreak investigation, and monitoring of common infectious conditions. Rapid immunodiagnostic kits are especially valuable in clinics because they can deliver actionable results without complex laboratory infrastructure, supporting faster treatment and isolation decisions.

Approximately 32% of Immunodiagnostic product development focuses on rapid cartridge formats, multiplex antigen detection, improved sensitivity, and digital result interpretation. Manufacturers are integrating optical readers and automated interpretation to reduce subjective assessment of test lines and improve consistency. Immunodiagnostic systems are expected to retain leadership because they balance speed, accessibility, and broad usability across Reference Laboratories, Veterinary Laboratories and Clinics, and Point of Care/In House Testing environments.

Molecular Diagnostic: Molecular Diagnostic technologies are projected to account for approximately 39% of market demand. PCR, real-time PCR, nucleic-acid amplification, and related methods are increasingly used where high sensitivity, pathogen differentiation, and early-stage detection are essential. Molecular Diagnostic systems are particularly important for respiratory disease, vector-borne infections, reproductive pathogens, and outbreaks requiring rapid confirmation.

Approximately 34% of molecular innovation activity focuses on multiplex PCR, automated extraction, portable amplification, and faster turnaround. Molecular Diagnostic technologies are expected to gain share because veterinary laboratories increasingly require broader pathogen panels and more precise identification. Reference Laboratories and Research Institutes and Universities remain major users, while compact molecular platforms are expanding access within veterinary clinics and point-of-care settings.

Others: Others are expected to represent approximately 15% of the Veterinary Infectious Disease Diagnostics Market. This category includes complementary diagnostic approaches used when immunodiagnostic or molecular testing alone does not provide sufficient information. These methods can support culture, microscopy, biochemical testing, and specialized confirmatory procedures across veterinary laboratories and research environments.

Approximately 20% of development activity within Others focuses on workflow automation, digital interpretation, and combination testing strategies. These methods remain important where pathogen isolation, antimicrobial susceptibility, or morphological confirmation is required. The segment is expected to maintain stable demand as laboratories continue combining several technologies to improve diagnostic confidence.

By Applications

Reference Laboratories: Reference Laboratories are expected to dominate application demand with approximately 36% share. These facilities process large test volumes and provide specialized molecular, immunodiagnostic, confirmatory, and surveillance services to veterinary clinics, livestock operations, and animal-health organizations. Their centralized infrastructure allows them to maintain advanced instrumentation, trained personnel, and broad diagnostic menus covering multiple animal species and pathogen categories.

Approximately 38% of Reference Laboratory modernization focuses on automated sample preparation, multiplex testing, digital reporting, and high-throughput workflows. These laboratories are expected to remain the leading application because they can perform complex testing that smaller clinics may not economically support. Strong connections with veterinary practices and commercial livestock customers also provide consistent sample volumes and support rapid introduction of new assays.

Veterinary Laboratories and Clinics: Veterinary Laboratories and Clinics are projected to account for approximately 30% of application demand. These facilities increasingly combine routine in-house screening with external laboratory confirmation, allowing veterinarians to make faster decisions for common infectious conditions while preserving access to specialized testing. Companion-animal hospitals represent an important source of demand because owners increasingly expect rapid diagnosis and targeted treatment.

Approximately 33% of clinic modernization focuses on compact analyzers, digital interpretation, rapid immunoassays, and integrated reporting. Larger veterinary hospitals are also adopting molecular platforms for same-day infectious disease testing. The segment is expected to grow steadily as clinics improve diagnostic capability and seek to reduce delays between patient examination and treatment decisions.

Point of Care/In House Testing: Point of Care/In House Testing is expected to represent approximately 23% of market demand. Rapid tests support immediate decisions in veterinary clinics, mobile practices, shelters, farms, and emergency environments. These systems are particularly useful for contagious diseases where quick isolation or treatment decisions are important.

Approximately 34% of emerging commercial opportunity is associated with portable analyzers, cartridge molecular systems, and same-visit diagnostic workflows. Growth is expected to remain strong as manufacturers simplify testing procedures and reduce instrument size. Wider adoption will depend on maintaining laboratory-quality performance while minimizing user training and sample preparation requirements.

Research Institutes and Universities: Research Institutes and Universities are projected to account for approximately 11% of application demand. These organizations conduct pathogen surveillance, assay validation, epidemiological research, sequencing, and development of new veterinary diagnostic targets. Academic laboratories also support investigation of emerging and zoonotic diseases affecting animal and human health.

Approximately 24% of research-oriented diagnostic development focuses on emerging pathogens, sequencing, assay validation, and surveillance methods. Research Institutes and Universities remain important innovation partners for commercial manufacturers because they help identify new disease targets and validate next-generation testing approaches across multiple species.

Veterinary Infectious Disease Diagnostics Market Regional Outlook

Global Veterinary Infectious Disease Diagnostics Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America is expected to lead the Veterinary Infectious Disease Diagnostics Market with approximately 38% share. The region benefits from advanced veterinary hospitals, extensive reference laboratory networks, strong companion-animal expenditure, and large commercial livestock operations. The United States remains the largest regional market because veterinary practices routinely use infectious disease testing across both companion and production animals.

Regional growth is supported by laboratory automation, rapid molecular testing, livestock surveillance, and growing use of point-of-care diagnostics. North America is expected to maintain leadership as clinics continue expanding in-house testing while centralized laboratories increase high-throughput molecular capacity.

Europe

Europe is projected to account for approximately 27% of market demand. Germany, France, the United Kingdom, Italy, and other major veterinary markets support strong adoption through companion-animal care, livestock biosecurity, food-animal monitoring, and academic research. Regional laboratories increasingly use multiplex molecular methods for faster pathogen differentiation.

Development is supported by strong veterinary regulation and structured animal disease surveillance. Europe is expected to remain a major market as producers and clinicians continue prioritizing early disease detection, antimicrobial stewardship, and improved laboratory connectivity.

Asia-Pacific

Asia-Pacific is expected to hold approximately 25% of the Veterinary Infectious Disease Diagnostics Market. Growth is supported by large livestock populations, expanding companion-animal ownership, growing veterinary infrastructure, and increasing awareness of zoonotic disease surveillance across China, India, Japan, South Korea, and Southeast Asia.

Regional demand is expected to strengthen as veterinary laboratories expand molecular testing and livestock producers increase routine surveillance. Asia-Pacific provides significant long-term opportunity for portable and affordable diagnostics capable of serving both urban clinics and distributed agricultural environments.

Middle East and Africa

The Middle East and Africa are projected to account for approximately 6% of market demand. Veterinary diagnostics are increasingly used across livestock production, animal import control, companion-animal clinics, and disease surveillance programs. Demand is concentrated in major urban veterinary centers and commercially important livestock regions.

Growth is expected to remain strongest where governments and producers invest in biosecurity and outbreak monitoring. Portable diagnostics and point-of-care platforms provide particular opportunity because they can extend testing into areas located far from centralized laboratories.

Rest of the World

Rest of the World is expected to represent approximately 4% of market demand, including emerging diagnostic activity across Latin America and smaller veterinary markets. Demand is supported by cattle production, poultry, companion animals, and increasing awareness of infectious disease control.

Growth is expected to remain gradual as laboratory networks expand and more clinics adopt rapid testing. Affordable immunodiagnostic kits and portable molecular systems are likely to play an important role in improving diagnostic access across geographically dispersed veterinary populations.

List of Top Veterinary Infectious Disease Diagnostics Market Companies

  • Abbott Laboratories
  • Biomérieux SA
  • Creative Diagnostics
  • HESKA Corporation
  • Innovative Diagnostics
  • IDEXX Laboratories Inc.
  • Neogen Corporation
  • Qiagen N.V.
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific Inc
  • Virbac

Top Two Companies with Highest Market Share

  • IDEXX Laboratories Inc.: IDEXX Laboratories Inc. is estimated to hold approximately 22% share among the supplied companies, supported by broad veterinary diagnostic portfolios, reference laboratory services, in-clinic testing platforms, and extensive companion-animal customer relationships.
  • Thermo Fisher Scientific Inc: Thermo Fisher Scientific Inc is estimated to account for approximately 15% share among the supplied companies, supported by molecular diagnostic technologies, PCR capabilities, laboratory instrumentation, and broad animal-health research applications.

Investment Analysis and Opportunities

Investment activity in the Veterinary Infectious Disease Diagnostics Market is increasingly focused on multiplex molecular testing, automated laboratory workflows, rapid point-of-care platforms, and digitally connected veterinary diagnostics. Approximately 34% of current investment priorities are associated with molecular assay expansion, portable PCR, automated extraction, and faster interpretation. Immunodiagnostic remains an important investment category because it accounts for approximately 46% of product demand and provides broad accessibility across clinics and laboratories.

Reference Laboratories remain the strongest application opportunity because they account for approximately 36% of demand and provide infrastructure for specialized and high-throughput testing. Point of Care/In House Testing offers substantial future potential as veterinary clinics and livestock operators seek faster decisions. North America remains the leading regional investment environment, while Asia-Pacific offers significant long-term expansion through livestock surveillance and improving veterinary infrastructure. Companies that combine laboratory systems with portable diagnostic platforms can serve both centralized and decentralized testing environments.

New Product Development

New product development in the Veterinary Infectious Disease Diagnostics Market is increasingly centered on multiplex testing, faster molecular amplification, automated sample preparation, and simplified point-of-care operation. Approximately 34% of current innovation activity focuses on PCR panels capable of identifying multiple pathogens from one sample. These systems can reduce diagnostic delay when animals present with similar clinical symptoms caused by different infectious agents. Developers are also improving reagent stability and cartridge design so advanced testing can move beyond centralized laboratories.

Approximately 25% of recent product-development activity focuses on rapid molecular testing and broader pathogen panels. Manufacturers are also integrating digital readers, automated interpretation, and connected reporting into immunodiagnostic systems. Future products are expected to place greater emphasis on portability, species-specific validation, low sample volume, and simplified workflows. Diagnostic platforms capable of supporting companion animals and production livestock through modular assay menus are likely to gain stronger adoption.

Five Recent Developments

  • February 2026 - Multiplex Molecular Panels Expand Further: Veterinary diagnostic developers increased broader pathogen coverage, with approximately 34% of innovation activity focused on PCR-based multiplex detection and automated molecular workflows.
  • March 2026 - Point-of-Care Testing Adoption Accelerates: Veterinary clinics expanded rapid in-house diagnostics, with approximately 23% of application demand associated with Point of Care/In House Testing.
  • April 2026 - Reference Laboratory Automation Advances: Centralized laboratories increased high-throughput processing, with approximately 38% of modernization activity focused on automated preparation, multiplex testing, and digital reporting.
  • May 2026 - Livestock Surveillance Programs Strengthen: Animal-health organizations expanded infectious disease monitoring, with approximately 35% of growth-oriented diagnostic demand linked to livestock and zoonotic disease surveillance.
  • June 2026 - Rapid Molecular Platforms Gain Momentum: Diagnostic manufacturers increased portable testing capability, with approximately 25% of recent development activity focused on faster molecular systems and broader pathogen panels.

Report Coverage of Veterinary Infectious Disease Diagnostics Market

The Veterinary Infectious Disease Diagnostics Market report provides detailed coverage across Immunodiagnostic, Molecular Diagnostic, and Others product types, with analysis of pathogen detection, sample preparation, rapid testing, laboratory automation, assay validation, multiplex testing, point-of-care workflows, and digital interpretation. Application coverage includes Reference Laboratories, Veterinary Laboratories and Clinics, Point of Care/In House Testing, and Research Institutes and Universities. The report examines companion-animal diagnostics, livestock surveillance, zoonotic disease monitoring, outbreak investigation, biosecurity, and veterinary treatment support.

Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of the World, with attention to veterinary infrastructure, livestock production, companion-animal care, diagnostic accessibility, and laboratory development. Competitive coverage includes Abbott Laboratories, Biomérieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc, and Virbac. The report further examines laboratory automation, molecular diagnostics, rapid testing, multiplex assay development, infectious disease surveillance, and the continued evolution of veterinary diagnostics toward faster, more decentralized, and more connected testing systems.

Veterinary Infectious Disease Diagnostics Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 2439.08 Million in 2026

Market Size Value By

USD 4879.77 Million by 2035

Growth Rate

CAGR of 8.01% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Immunodiagnostic
  • Molecular Diagnostic
  • Others

By Application :

  • Reference Laboratories
  • Veterinary Laboratories and Clinics
  • Point of Care/In House Testing
  • Research Institutes and Universities

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Veterinary Infectious Disease Diagnostics Market is expected to reach USD 4879.77 Million by 2035.

The Veterinary Infectious Disease Diagnostics Market is expected to exhibit a CAGR of 8.01% by 2035.

Abbott Laboratories, Biomérieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc, Virbac

In 2026, the Veterinary Infectious Disease Diagnostics Market value will reach at USD 2439.08 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified